CD274 and neoplasm: Other biomarkers that are associated with improved response to immune checkpoint blockade across a variety of tumor types include high tumor mutational burden, positive PD-L1 expression (in cancer cells and cells in the TME), and T-cell-inflamed gene expression profile [28].